Objective: Studies have shown that common single-nucleotide polymorphisms (SNPs) in the serotonin 5-HT-2C receptor (HTR2C) are associated with antipsychotic agent-induced weight gain and the development of behavioural and psychological symptoms. We aimed to analyse whether variation in the HTR2C is associated with obesity-and mental health-related phenotypes in a large population-based cohort. Method: Six tagSNPs, which capture all common genetic variation in the HTR2C gene, were genotyped in 4978 men and women from the European Prospective Investigation into Cancer (EPIC)-Norfolk study, an ongoing prospective populationbased cohort study in the United Kingdom. To confirm borderline significant associations, the À759C/T SNP (rs3813929) was genotyped in the remaining 16 003 individuals from the EPIC-Norfolk study. We assessed social and psychological circumstances using the Health and Life Experiences Questionnaire. Genmod models were used to test associations between the SNPs and the outcomes. Logistic regression was performed to test for association of SNPs with obesity-and mental healthrelated phenotypes. Results: Of the six HTR2C SNPs, only the T allele of the -759C/T SNP showed borderline significant associations with higher body mass index (BMI) (0.23 kg m -2 ; (95% confidence interval (CI): 0.01-0.44); P ¼ 0.051) and increased risk of lifetime major depressive disorder (MDD) (Odds ratio (OR): 1.13 (95% CI: 1.01-1.22), P ¼ 0.02). The associations between the À759C/T and BMI and lifetime MDD were independent. As associations only achieved borderline significance, we aimed to validate our findings on the -759C/T SNP in the full EPIC-Norfolk cohort (n ¼ 20 981). Although the association with BMI remained borderline significant (b ¼ 0.20 kg m -2 ; 95% CI: 0.04-0.44, P ¼ 0.09), that with lifetime MDD (OR: 1.01; 95% CI: 0.94-1.09, P ¼ 0.73) was not replicated. Conclusions: Our findings suggest that common HTR2C gene variants are unlikely to have a major role in obesity-and mental health-related traits in the general population.
Introduction
The serotonin (5-hydroxytryptamine (5-HT)) neurotransmitter has been implicated in a variety of complex neurological, psychiatric and behavioural disorders, including depression, anxiety, schizophrenia, obsessive-compulsive disorder and appetite. 1 Furthermore, animal studies using knockout mice have shown that the serotonin 5-HT-2C receptor (HTR2C) gene, located on chromosome Xq24, is involved in the control of appetite and feeding behaviour and development of obesity. [2] [3] [4] [5] [6] A functional variant (G4C polymorphism), resulting in a Cys-to-Ser missense mutation at codon 23, was identified by screening the HTR2C gene in a Caucasian population comprising individuals with and without mental disorders. 7 This Cys23Ser variant (rs6318) has been implicated in eating 8, 9 and anxiety 10 disorders and reduction in weight gain in the treatment of obesity. 11 However, other studies failed to confirm the association of Cys23Ser variant with the risk of bullimia, binge eating disorder and obesity. 12, 13 Studies in schizophrenic patients have shown significant association between polymorphisms in the promoter of HTR2C gene and weight gain induced by antipsychotic drugs. [14] [15] [16] [17] [18] The C allele of the -759C/T variant, located in the promoter region, has been shown to associate with a higher incidence of weight gain. Consistently, a study in 120 obese and 104 non-obese women reported association of the C allele with obesity (Odds ratio (OR): 1.72 (95% confidence interval (CI): 1.13-2.64), P ¼ 0.008). 19 Studies examining the genetic variation in HTR2C have typically been small and the largest study so far, comprising 466 non-obese and 123 obese men, found the frequency of the C allele of the À697C/G variant, another polymorphism in the 5 0 promoter region, to be higher in non-obese than in obese men (OR: 2.5; 95% CI: 1.3-5.1, P ¼ 0.009). 20 In contrast, a few studies failed to observe an association between the HTR2C polymorphisms in the promoter and obesity-related traits. 21, 22 So far, the contribution of genetic variation in HTR2C to common obesity and traits of depression in large-scale and population-based cohorts has not been examined. Hence, in this study, we investigated the association between common genetic variation in HTR2C and obesityand mental health-related traits in the European Prospective Investigation into Cancer (EPIC)-Norfolk study. Besides the three commonly studied single-nucleotide polymorphisms (SNPs) (À759C/T, À697C/G and Cys23Ser), we selected three additional tagSNPs (single nucleotide polymorphisms) to ensure full coverage of the genetic variation of the HTR2C gene and tested for association with obesity-and mental health-related traits in single SNP and haplotype analyses.
Materials and methods

Study population
The study includes 4978 participants that were randomly selected from the EPIC-Norfolk study, an ongoing prospective population-based cohort study comprising 25 631 residents living in the city of Norwich and its surrounding towns and rural areas. It is an ethnically homogeneous population of white European origin. All men and women, aged 39-79 years from the consenting general practices, completed a baseline health examination between 1993 and 1997. From January 1998, we invited the cohort for a second health examination and 15 786 people had attended by October 2000. For the purposes of this analysis, we examined data from a random sample of 5000 participants who attended the second health examination and who were free of baseline disease (cancer, coronary heart disease and diabetes) with fully arrayed DNA available, completed food frequency questionnaire data, and blood HbA1C and body mass index (BMI) measured at the two clinical assessments. Full details on participant recruitment and study procedures have been described previously. 23, 24 In brief, trained nurses examined the study participants; height and weight were measured, and BMI was calculated as weight (kg) height
). Waist was measured at the minimum circumference at the natural waistline between the lower rib margins and iliac crest, or at the level of the umbilicus if there was no natural waistline. Anthropometric measures and genotypic data were available for 4978 men and women. Descriptive characteristics for the cohort are shown in Table 1 .
We also carried out an assessment of social and psychological circumstances using the Health and Life Experiences Questionnaire (HLEQ). The HLEQ included a structured selfassessment approach to psychiatric symptoms that enabled application of restricted Diagnostic and Statistical Manual of Mental Disorders-IV 25 criteria for episodic major depressive disorder (MDD). The assessment, designed to identify those study participants thought likely to have met a putative diagnosis of MDD at any time in their lives, depends on participants initially disclosing details of their most recently experienced episode of depression (if more than one) that has endured for 2 weeks or more and that fulfils the required concurrent Diagnostic and Statistical Manual of Mental Disorders-IV MDD symptom criteria. In addition, operational criteria for clinically significant impairment and help seeking were included and participants were requested to estimate episode onset and (if appropriate) offset timings. 26 Past-year MDD was defined as any episode that was either Table 1 Clinical characteristics of the participants in the EPIC-Norfolk study
Clinical characteristics of the initial study sample (n ¼ 4978) 27 The MHI-5 was scored on a scale from 0 to 100 in which a lower score represents greater psychological distress. The MHI-5 has been shown to be an effective measure of depression severity. 28 In addition, the HLEQ included an assessment of neuroticism through completion of a short form of the Eysenck Personality Questionnaire, 29 and scored within the range from 0 to 12 with higher scores indicating increased neuroticism. Depression is a neurological disorder with a range of psychiatric symptoms and hence, several behavioural and emotional measures are required to capture this trait. Antidepressant medication use during a 1-week preassessment period was obtained through self-report questionnaire, and was completed approximately 6 months before the assessment of MDD status. Antidepressant medication use was defined according to the British National Formulary (section 4.3), and included tricyclic (or related) antidepressants, monoamine-oxidase inhibitors, selective serotonin reuptake inhibitors (and related antidepressants), and other antidepressants.
To validate borderline associations, we genotyped the remaining 16 003 individuals of the EPIC-Norfolk cohort (n total ¼ 20 981) for one of the HTR2C SNPs (that is, À759C/ T). Descriptive characteristics are shown in Table 1 .
The study was approved by the Norfolk, United Kingdom, Health District ethics committee and all participants gave informed consent.
TagSNP selection
The HTR2C gene is located on chromosome Xq24, spans 326.1 kb and comprises six exons. SNPs in the HTR2C gene were selected using genotype data from the International HapMap Phase II collected in individuals of Northern and Western European ancestry (CEU) (HapMap data release 19 2005, dbSNP b124). The Haploview software V3.3 (http:// www.broadinstitute.org/haploview/haploview-downloads) was used to assess the linkage disequilibrium structure between SNPs. 30 As the HTR2C gene is located on the X-chromosome, linkage disequilibrium was assessed in women only. Tagger software was used to select tagSNPs with the 'pairwise tagging only' option and an r 2 threshold of 40.8.
There were 335 SNPs encompassing the HTR2C gene in the Hapmap for the CEU population. Of these 335 SNPs, 208 met the pre-requisite criteria (minor allele frequency X5% and Hardy-Weinberg equilibrium P-value40.01) for inclusion in analyses (Supplementary Figure 1) . In the tagSNP selection, we force included the three SNPs previously studied before running tagger. In total, six tagSNPs (rs3813929 (À759 C/T), rs518147 (À697 C/G), rs6318 (Ser23Cys), rs17260600 (IVS4 þ 55492A/C), rs6644093 (IVS4 þ 98007G/T) and rs1801412 ( þ 1553T/G)) representing the entire common genetic variations across the HTR2C gene were chosen for the study (Figure 1 ).
Genotyping
The six tagSNPs were genotyped using the Taqman platform (Applied Biosystems, Warrington, UK). The genotyping assays were carried out on 10 ng of genomic DNA in a 5 ml 384-well TaqMan assay using a G-Storm GS4 Thermal Cycler (GRI, Rayne, UK), cycling 95 1C for 10 min, and then 50 cycles of 15 s at 92 1C and 1 min at 60 1C. The ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) was used for end-point detection and allele calling. Genotype data were reviewed independently for each of the six SNPs and the call rate ranged from 97 to 99%. All six SNPs showed no significant departure from Hardy-Weinberg equilibrium (P 40.01, Supplementary Table 1) .
Statistical analysis
A likelihood ratio test was performed in women only (as HTR2C is located on the X-chromosome) to assess whether the observed genotypes were in Hardy-Weinberg equilibrium. We performed allelic association analyses, which allow combining men and women in one analysis, to preserve statistical power. Genmod models were used to test HTR2C polymorphisms, BMI and mental health KS Vimaleswaran et al the associations between the SNPs and the outcomes comparing the major and minor alleles. Logistic regression analysis adjusted for age and sex was carried out to test for the association of HTR2C SNPs with obesity-and mental health-related phenotypes. Mediation effects were tested by adjusting for BMI when examining the association of the HTR2C SNPs with depression and adjusting for depression when examining the association of HTR2C SNPs with BMI. Haplotype blocks were defined using Gabriel's method, as implemented in Haploview. Haplotype analyses were carried out for two-marker and six-marker haplotypes. Haplotype frequencies were estimated using the HAPLOTYPE procedure in SAS/Genetics version 9.1 (SAS Institute Inc., Cary, NC, USA). Haplotypes prevalent at 45% were retained for further haplotype analyses. Haplotype trend regression analysis was performed to test for association between common haplotypes and BMI. All statistical analyses for single point and haplotype association tests were carried out using SAS/ Genetics version 9.1 (SAS Institute Inc.).
Results
Of the six HTR2C SNPs, only the T allele of À759C/T showed borderline significant association with a 0.23 kg m -2 higher BMI compared with the C allele carriers (P ¼ 0.051) ( Table 2 ). The association with BMI remained unchanged after excluding individuals who use antidepressant medication (n ¼ 191) (0.27 kg m -2 (95% CI: 0.03-0.50), P ¼ 0.04). However, the À759C/T SNP was not associated with the increased risk of obesity (P ¼ 0.40) ( Table 3 ). In addition, the T allele of À759C/T SNP was also associated with an increased risk of lifetime MDD (OR: 1.11; 95% CI: 1.02-1.16, P ¼ 0.02) ( Table 3) . We also tested for the association of the SNP with lifetime MDD after excluding individuals on antidepressant medication and found that the OR was somewhat more pronounced (OR: 1.25; 95% CI: 1.03-1.51, P ¼ 0.02). The associations of the À759C/T SNP with BMI and lifetime MDD were independent; that is, the association between the À759C/T SNP and BMI remained significant and effect sizes were similar after adjusting for lifetime MDD (b ¼ 0.27 kg m -2 ; 95% CI: 0.03-0.51, P ¼ 0.03) and, vice versa, the association between the SNP and MDD remained significant after adjusting for BMI (OR: 1.11; 95% CI: 1.02-1.22, P ¼ 0.02). This shows that the association with BMI was not mediated through lifetime MDD and the association with lifetime MDD was not mediated through BMI.
As the observed associations were only borderline significant, we aimed to validate these findings in the full EPIC-Norfolk cohort (n ¼ 20 981). We found that the association of the SNP with BMI remained borderline (b ¼ 0.20 kg m In addition to À759C/T SNP, the T allele of the SNP IVS4 þ 98007G/T (rs6644093) was associated with an increased risk of lifetime MDD (OR: 1.12; 95% CI: 1.02-1.40, P ¼ 0.02) even after adjusting for age, sex and BMI. However, we did not observe an association of this SNP with the obesity-related traits (Tables 2 and 3) .
None of the other SNPs showed an association with obesity traitsFBMI and waist and mental health-related traitsFneuroticism, MHI-5, past-time and lifetime MDD.
After the single SNP allelic association, the two promoter SNPs, À759C/T and À697C/G, were analysed as two-marker and six-marker haplotypes. The haplotype frequencies are presented in the Supplementary Table 2 . None of the twomarker and six-marker haplotypes were significantly associated with obesity-and mental health-related phenotypes.
Discussion
In this study, we have assessed the association of six tagSNPs and haplotypes encompassing the HTR2C gene with obesityand mental health-related phenotypes in 4958 individuals and, because of borderline significance, we also tested whether the associations still prevailed in the full cohort , which is equivalent to B0.95 kg in body weight for a person of 1.70-m tall). The finding that the T allele of the À759C/T polymorphism is associated with BMI in our study is in contrast to the other investigations 32, 33 that found a significant association of the C allele with increased BMI. This could be due to the fact that these studies were performed in patients who were on medication, although our study included healthy individuals. In addition, we observed that the T allele of the À759C/T polymorphism was also associated with MDD. Given the fact that obesity and depression are associated traits, 34, 35 we tested for mediation effects and found that the association of À759C/T polymorphism with BMI was not mediated through MDD and vice versa. As our initial association analyses showed borderline significance for the À759C/T polymorphism, we genotyped this SNP in the remaining 16 003 individuals from the EPIC-Norfolk study to increase statistical power as well as to confirm whether the observed associations were truly positive. However, we found that the -759C/T SNP did not show any association with BMI and MDD. One of the main strengths of this study is the availability of variables such as MHI-5, a more general measure of psychological distress and a measure of depression severity 28, 36, 37 and neuroticism, a marker of liability to major depression, 38 alongside the HLEQ measure of MDD defined according to diagnostic criteria. When the two promoter polymorphisms, À759C/T and À697C/G, were combined as a two-marker haplotype, there was no association of the haplotypes with BMI and MDD. This was in contrast to the findings from a Japanese study 20 (n ¼ 589) and a Swedish study 39 (46 schizophrenic patients),
who showed an association of the haplotypes comprising the two promoter polymorphisms with obesity. In summary, this large-scale population-based study suggests that HTR2C gene variants are unlikely to have a major role in obesity-and mental health-related traits in a general population of white adult Europeans. HTR2C polymorphisms, BMI and mental health KS Vimaleswaran et al
